Home › Fuchs' Endothelial Dystrophy › NCT06261346
Plasma Rich in Growth Factors in Corneal Endothelial Transplantation
Recruiting
Safety and Efficacy of Brief Intraoperative Corneal Endothelial Graft Incubation in Plasma Rich in Growth Factors (PRGF) for Reducing Postoperative Endothelial Cell Loss
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: * undergoing endothelial keratoplasty (DSEK or DMEK) at the Bascom Palmer Eye Institute or Price Vision Group, using corneal graft tissue within 14 days of preservation Exclusion Criteria: * History of corneal transplantation in the study eye, Best corrected visual acuity (BCVA) worse than 20/40 in the contralateral eye, systemic immunosuppression, previous intraocular surgical procedures (other than cataract surgery) such as glaucoma tubes or silicone oil. The following special populations will be excluded. * Adults unable to consent * Pregnant women * Prisoners
About the study
The purpose of the study is to determine the safety and efficacy of brief intraoperative corneal endothelial graft incubation in plasma rich in growth factors (PRGF) for reducing postoperative endothelial cell loss.
What is being tested
- Endothelial keratoplasty (procedure)
- PRGF (biological)
Sponsor: University of Miami · Participants: 100 · Started: Jul 15, 2024
Contact the study team
- Alfonso L Sabater, MD · Phone: 3053266326
- Marianne Price, PhD · Phone: 317-814-2990
Official record on ClinicalTrials.gov — NCT06261346
Locations in the U.S.
| Florida | Bascom Palmer Eye Institute, Miami |
| Indiana | Price Vision Group, Indianapolis |
Conditions
From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.